Japan OKs Honebuto Paper with No Mention of Drug Pricing; Stable Supply, Innovation, Biosimilar Promotion Spelled Out

Japan’s Cabinet approved the 2022 Basic Policy for Economic and Fiscal Management and Reform ( honebuto ) on June 7, which included no mention of pharmaceutical pricing but called for ensuring the quality and stable supply of medicines and boosting...read more